Castle Biosciences, Inc. (CSTL) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: 27.82
30Y Low27.8·High29.1
P/FCF
↑
22.70
↓-26% vs avg
5yr avg: 30.57
30Y Low21.3·High49.0
P/B Ratio
↓
1.30
↓-33% vs avg
5yr avg: 1.95
30Y Low1.5·High3.5
ROE
↑
-5.2%
↓+34% vs avg
5yr avg: -7.9%
30Y Low-17%·High14%
Debt/EBITDA
N/A
—
5yr avg: 1.07
30Y Low1.1·High3.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CSTL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Castle Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 22.7x P/FCF, 26% below the 5-year average of 30.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $643M | $1.1B | $780M | $578M | $613M | $1.1B | $1.3B | $298M | — | — |
| Enterprise Value | $563M | $1.0B | $686M | $495M | $504M | $756M | $861M | $224M | — | — |
| P/E Ratio → | -25.54 | — | 42.98 | — | — | — | — | — | — | — |
| P/S Ratio | 1.87 | 3.28 | 2.35 | 2.63 | 4.48 | 11.45 | 20.29 | 5.74 | — | — |
| P/B Ratio | 1.30 | 2.39 | 1.71 | 1.48 | 1.54 | 2.62 | 3.06 | 3.50 | — | — |
| P/FCF | 22.70 | 39.81 | 21.34 | — | — | — | 248.55 | 48.96 | — | — |
| P/OCF | 9.99 | 17.52 | 12.02 | — | — | — | 128.85 | 42.42 | — | — |
P/E links to full P/E history page with 30-year chart
CSTL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.04 | 2.07 | 2.25 | 3.68 | 8.04 | 13.75 | 4.32 | — | — |
| EV / EBITDA | — | — | 27.82 | — | — | — | — | 29.12 | — | — |
| EV / EBIT | — | — | 31.00 | — | — | — | — | 22.57 | — | — |
| EV / FCF | — | 36.99 | 18.78 | — | — | — | 168.41 | 36.83 | — | — |
CSTL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Castle Biosciences, Inc. earns an operating margin of -12.4%. Operating margins have expanded from -30.9% to -12.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -5.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.4% | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% | 84.5% | 85.9% | 76.8% | 64.2% |
| Operating Margin | -12.4% | -12.4% | 2.6% | -30.9% | -53.2% | -42.6% | -10.4% | 14.1% | -16.8% | -79.2% |
| Net Profit Margin | -7.0% | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% | -16.4% | 10.2% | -27.9% | -89.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.2% | -5.2% | 4.3% | -14.5% | -16.6% | -7.6% | -4.1% | 14.1% | — | — |
| ROA | -4.4% | -4.4% | 3.7% | -12.8% | -14.8% | -6.9% | -3.7% | 7.4% | -39.5% | -126.0% |
| ROIC | -8.5% | -8.5% | 1.9% | -17.1% | -28.8% | -62.5% | -57.0% | 51.5% | -44.0% | -262.1% |
| ROCE | -8.6% | -8.6% | 2.0% | -16.6% | -17.2% | -9.4% | -2.5% | 12.2% | -37.9% | -237.0% |
CSTL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $117M exceeds total debt of $37M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.06 | 0.04 | 0.03 | 0.02 | — | 0.30 | — | — |
| Debt / EBITDA | — | — | 1.07 | — | — | — | — | 3.27 | — | — |
| Net Debt / Equity | — | -0.17 | -0.20 | -0.21 | -0.27 | -0.78 | -0.99 | -0.87 | — | — |
| Net Debt / EBITDA | — | — | -3.79 | — | — | — | — | -9.59 | — | — |
| Debt / FCF | — | -2.82 | -2.56 | — | — | — | -80.14 | -12.13 | — | — |
| Interest Coverage | -342.19 | -342.19 | 38.37 | -5214.00 | -4052.18 | -40011.00 | -2.87 | 2.17 | -1.80 | -6.49 |
Net cash position: cash ($117M) exceeds total debt ($37M)
CSTL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Castle Biosciences, Inc.'s current ratio of 5.26x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.20x to 5.26x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.26 | 5.26 | 7.29 | 6.20 | 8.09 | 14.21 | 20.58 | 7.63 | 2.69 | 1.28 |
| Quick Ratio | 5.11 | 5.11 | 7.13 | 6.04 | 7.98 | 14.13 | 20.47 | 7.55 | 2.56 | 1.22 |
| Cash Ratio | 4.36 | 4.36 | 5.93 | 5.10 | 7.16 | 13.25 | 19.63 | 6.47 | 0.66 | 0.23 |
| Asset Turnover | — | 0.59 | 0.63 | 0.48 | 0.31 | 0.20 | 0.14 | 0.43 | 1.02 | 1.40 |
| Inventory Turnover | 6.93 | 6.93 | 7.40 | 5.66 | 8.04 | 7.83 | 4.37 | 5.91 | 6.00 | 16.16 |
| Days Sales Outstanding | — | 46.00 | 56.30 | 63.61 | 62.53 | 67.05 | 74.34 | 103.09 | 193.67 | 123.46 |
CSTL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Castle Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 2.3% | — | — | — | — | — | — | — |
| FCF Yield | 4.4% | 2.5% | 4.7% | — | — | — | 0.4% | 2.0% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $29M | $29M | $27M | $26M | $25M | $19M | $9M | $11M | $10M |
Peer Comparison
Compare CSTL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CSTLYou | $643M | -25.5 | — | 22.7 | 79.4% | -12.4% | -5.2% | -8.5% | — |
 NTRA | $33B | -150.5 | — | 300.3 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 VCYT | $4B | 64.9 | 41.0 | 33.5 | 69.6% | 14.3% | 5.3% | 5.6% | 0.4 |
 ARDX | $2B | -24.5 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 FLGT | $531M | -9.1 | — | — | 40.6% | -28.2% | -5.4% | -6.4% | — |
 GH | $17B | -38.8 | — | — | 64.5% | -44.4% | — | -34.9% | — |
 ILMN | $25B | 29.6 | 22.6 | 26.3 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 CDNA | $1B | -62.6 | — | 35.8 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 PACB | $410M | -0.7 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 LH | $21B | 24.3 | 12.6 | 17.4 | 26.8% | 10.9% | 10.5% | 7.8% | 3.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CSTL — Frequently Asked Questions
Quick answers to the most common questions about buying CSTL stock.
What is Castle Biosciences, Inc.'s P/E ratio?
Castle Biosciences, Inc.'s current P/E ratio is -25.5x. The historical average is 43.0x.
What is Castle Biosciences, Inc.'s ROE?
Castle Biosciences, Inc.'s return on equity (ROE) is -5.2%. The historical average is -4.2%.
Is CSTL stock overvalued?
Based on historical data, Castle Biosciences, Inc. is trading at a P/E of -25.5x. Compare with industry peers and growth rates for a complete picture.
What are Castle Biosciences, Inc.'s profit margins?
Castle Biosciences, Inc. has 79.4% gross margin and -12.4% operating margin.